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Abstract 
BACKGROUND: Angiogenesis is vital for development of normal tissue and wound healing; but it play an important 
role in development of some diseases such as different types of cancer. Vascular endothelial growth factor (VEGF) 
and VEGF receptors (VEGFR) are two important key factors in this process. Previous studies have shown that down-
regulation of VEGFR1 inhibits cell proliferation, migration, and vascular permeability of endothelial cells. So, 
blocking VEGF and VEGFR1 have been considered as a target to prevent the growth of tumors. 
METHODS: In this study, VEGFR1 gene expression was suppressed in AGS and SNU5 cancer cells using RNA 
interference (RNAi) technology. Down-regulation of VEGFR1 was assessed at mRNA and protein levels using real-
time polymerase chain reaction (PCR), and western blot methods. Moreover, the viability and apoptosis of these 
cells were analyzed using MTT and flow cytometry techniques. 
RESULTS: VEGFR1 expression was significantly down-regulated both in mRNA and protein levels. MTT and flow 
cytometry results revealed that down-regulation of VEGFR1 inhibited cell proliferation, and induced apoptosis of 
these cancer cells. 
CONCLUSION: Our findings suggest that VEGFR1 could play an important role in cell proliferation and tumor 
growth; and it could be considered as a valuable target for controlling tumor cells, and cancer therapies. 
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Introduction1 
After heart diseases, cancer is the second 
leading cause of morbidity and mortality 
worldwide,1 and many efforts and extensive 
studies have been carried out in the field of 
cancer treatment and prevention to date.2 
Vascular endothelial growth factor (VEGF) and 
its receptors (VEGFR) are the key regulators of 
physiologic angiogenesis, during organ 
development, embryogenesis, and 




reproduction, and plays a major role in the 
pathobiology of cancer and inflammatory 
diseases.3-6 They are structurally related 
members of the receptor tyrosine kinase (RTK) 
family, and secreted as glycoproteins that 
mediate critical signaling pathways for 
survival, proliferation, vascular permeability, 
and migration of endothelial cells by 
interaction of VEGF to its receptors, VEGFR1 
(or FLT1), VEGFR2 (KDR), and VEGFR3.7-9 
VEGFR2 is dominantly found in endothelial 
cells, but VEGFR1 is widely expressed in 
normal and malignant cells such as 
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cells, lung cancer, breast cancer, and pancreatic 
cancer and hematopoietic malignancies.10,11 
Some studies have shown that VEGFR1 plays 
an important role in malignant growth, and 
accelerate proliferation of transformed cells.12,13 
Furthermore, in-vivo and in-vitro studies on 
liver sinusoidal endothelial cells have revealed 
that VEGFR1 could induce expression of 
growth factors.14,15 VEGFR1 is different from 
other VEGFRs; because it could also be 
expressed in soluble form.13 Previous studies 
in some cancers such as breast cancer revealed 
that VEGFR1 was significantly upregulated in 
metastasis stage and was related to relapses, 
also was associated with shorter survival in 
resected breast cancer and early-stage non-
small cell lung cancer.13,16  
So, recent studies have considered VEGF 
and its receptors as crucial targets in inhibition 
of angiogenesis and growth of tumor cells.17 
Up-regulation of VEGF and its receptors such 
as VEGFR1 and VEGFR2 stimulates 
angiogenesis, while inhibition of these proteins 
using monoclonal antibodies or chemical 
inhibitors suppresses angiogenesis processes.18-21 
Previous studies such as clinical trials, using an 
aptamer22 or an antibody fragment23 that binds 
VEGF, have supported this ideal that VEGF 
pathway could be considered as a crucial 
therapeutic target for cancers therapy. Other 
studies used VEGFRs inhibition as an alternative 
strategy to antagonize VEGF.5,11,19-21 This is a 
great strategy because of its potency to inhibit 
multiple members of VEGF family at once.24  
RNA interference (RNAi) is a fundamental 
biological process of sequence-specific, post-
transcriptional gene silencing, by which 
animal and plant cells regulate gene 
expression. This process is initiated by 
complementary base-pairing of RNAi with 
target RNA, which recruits cellular RNases 
that mediate RNA degradation.25,26 These 
molecules are 19-23 double strand nucleotide, 
which is homologous in sequence to the 
silenced gene.27 The strategy of RNAi to inhibit 
gene expression and function has developed 
rapidly as a research tool to a promising 
therapeutic approach.28 This technology is now 
routinely used in scientific researches, and 
some biotechnology companies have reported 
the use of RNAi as therapeutic agents because 
of its potential to targeted gene silencing.29 
Small interfering RNAs (siRNAs) molecules 
are 19-23 double strand nucleotide sequences, 
which are homologous in sequence to the 
silenced genes, provide a useful means to 
selectively down-regulate mRNA transcripts 
and studying the function of gene products.30  
In this study, the mRNA expression of 
VEGFR1 was down-regulated using synthetic 
siRNA in AGS and SNU-5 cells. We showed 
that suppression of VEGFR1 inhibited cell 
proliferation and growth, and stimulated 
apoptosis of these cells. 
Materials and Methods 
AGS and SNU-5 cells (from Pasteur Institute, 
Tehran, Iran) were grown in Roswell Park 
Memorial Institute (RPMI)-1640 medium 
(Inoclon, Iran) containing 10% fetal bovine 
serum (FBS) (Gibco), streptomycin  
(100 µg/ml), and penicillin (100 U/ml) (Life 
Technologies). Cells were incubated in a 
humidified 5% CO2 incubator at 37 °C for 48 
hours, and passaged using trypsinization. Up-
regulate the expression of target gene was 
induced by hypoxic situation for 24 hours. 
Anti-VEGFR1 siRNA was designed with 
oligowalk online software. The siRNA 
sequenced designed to target VEGFR1 was 
GTGGCTACTCGTTAATTATCA. Working 
solution of siRNA was prepared according to 
manufacturer’s protocol and stored at -20 °C. 
AGS and SNU-5 cells were grown to ∼80% 
confluency in RPMI-1640 medium for 24 hours 
before transfection. Lipofectamine 2000 
(Invitrogen, USA) was used for transfection of 
anti-VEGFR1 siRNA according to 
manufacturer’s instructions. 
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genes, total RNA was extracted from the cells 
using TRIzol® Reagent (thermo fisher, US) 
according to the manufacturer’s instructions. 
Agarose gel electrophoresis and 
spectrophotometry (NanoDrop™ 2000, thermo 
scientific) were used to measure RNA quality 
and quantity, respectively. 2 µg of total RNA 
was used for cDNA synthesis using 2-steps 
real-time polymerase chain reaction (RT-PCR) 
kit (Vivantis Technologies, Selangor, Malaysia), 
and OligodT and Random Hexamer primers, 
according to the manufacturer’s instructions.  
mRNA expression levels of genes were 
evaluated using quantitative real-time (qRT) 
PCR method. Appropriate primers were 
designed using Snap Gene and Oligo 7 software. 
The mRNA expression of VEGFR1 (forward: 5'- 
GGCTTCTGACCTGTGAAGCAAC-3', reverse: 
5'- GAACTCTCGTGTTCAAGGGAGTG-3') was 
assessed and normalized to mRNA expression 
level of GAPDH (forward: 5'-
GTGAACCATGAGAAGTATGACAA-3', and 
reverse: 5'-CATGAGTCCTTCCACGATAC -3') 
as an internal control gene. 
qRT-PCR was performed using StepOne 
ABI system (Applied Biosystems, CA, USA). 
The final volume of reactions was 20 µl, which 
contained 20 ng of cDNA, 5X HOT FIREPol® 
EvaGreen® qPCR Mix Plus (ROX) (Solis 
BioDyne, Tartu, Estonia), and 200 nM of 
forward and reverse primers. The thermal 
reaction condition was as follows: 
denaturation of templates at 95 ºC for 5 
minutes, followed by 35 cycles of denaturation 
at 95 ºC for 15 seconds, and 
annealing/extension at 60 ºC for 30 seconds. 
Dissociation curve analysis and 2% agarose gel 
electrophoresis were used to verify the 
specificity of PCR products. 
To examine the protein expression level of 
VEGFR1, total protein was extracted from cells 
by radio-immunoprecipitation assay (RIPA) 
lysis buffer (150 mmol/l NaCl, 50 mmol/l Tris-
HCl, pH of 7.5, 1% Nonidet P-40, and 0.25% 
Na deoxycholate) containing protease 
inhibitors, and stored in -80 ºC. Protein 
samples were separated by electrophoresis on 
12% sodium dodecyl sulfate-polyacrylamide 
gel (SDS-PAGE), and then transferred to 
polyvinylidene fluoride (PVDF) membrane 
using Bio-Rad Trans-Blot® SD semi-dry 
system. Membranes were blocked with 5% 
(w/v) bovine serum albumin (BSA) in 
phosphate buffer saline (PBS) for 1 hour at 
room temperature, washed with PBS + 1% 
Tween20 (PBST), and then incubated with the 
following primary antibodies overnight at  
4 ºC; washed with PBST again, and incubated 
at room temperature with anti-rabbit 
secondary antibodies (Santa Cruz 
Biotechnology, CA, USA), goat polyclonal 
antibody actin (Cyto-Matin Gene, Iran) for  
1 hour. Proteins were visualized with ECL 
Western Blotting kit (Cyto-Matin Gene, Iran).  
Cells were seeded onto 96-well plates (103 
cells/well), and were subsequently incubated 
for 24 hours. Cell viability was assessed by the 
colorimetric 3-(4, 5-dimethylthiazol-2-yl)-2,  
5-diphenyltetrazolium bromide, methyl-
thiazol-tetrazolium (MTT) assay (Roche, 
Germany)31 at 24, 48, and 72 hours post 
transfection with anti-VEGFR1 siRNA. Quant 
Universal Microplate Spectrophotometer 
(BioTek, Winooski, VT) was used to measure 
the absorbance at 570 nm. 
Annexin-V-PI detection kit (Roche) was 
used to assess the number of apoptotic cells, 
according to manufacturer’s instruction. AGS 
and SNU-5 cells were seeded in a 24-well flat-
bottomed plate, and incubated for 24 hours at 
37 ºC, then transfected with anti-VEGFR1 
siRNA. 48 hours post transfection, cells were 
collected and washed with PBS, then 
resuspended with PI and Annexin V in the 
binding buffer (10 mM HEPES, 140 mM NaCl, 
2.5 mM CaCl2, and pH of 7.4). After  
15 minutes of  incubation at 37 ºC, cells were 
analyzed by flow-cytometer (FACScan™ 
system, Becton Dickinson, NJ, USA). 





http://cdjournal.muk.ac.ir,    15 January 
The effects of VEGFR1 on cancer cells Rahimi et al. 
  4   Chron Dis J, Vol. 6, No. 1, Winter 2018  
performed for analyzing data using Graphpad 
Prism 6 Demo and SPSS (version 22, IBM 
Corporation, Armonk, NY, USA). A P-value ≤ 
0.05 was considered significant, and data were 
shown as mean ± standard deviation (SD). 
Results 
mRNA expression level of VEGFR1: mRNA 
expression level of VEGFR1 was analyzed 
using qRT-PCR technique 48 hours post 
transfection of anti-VEGFR1 siRNA in AGS 
and SNU-5 cells. mRNA expression levels of 
VEGFR1 and GAPDH (as a reference gene) 
were assessed both in treated and untreated 
cells. T-test analysis of qRT-PCR results 
revealed that the mRNA expression level of 
VEGFR1 gene decreased significantly in both 
cells transfected with siRNA compared to non-
treat cells (Figure 1). This findings indicated 
that anti-VEGFR1 siRNA application 




Figure 1. The quantitative analysis of expression 
level of VEGFR1 gene down-regulated in AGS and 
SNU-5 cells after treatment with anti-VEGFR1 
siRNA. Each real-time PCR examination was 
carried out at least in triplicate. Data are shown as 
fold change in relative expression compared with 
GAPDH on the basis of Comparative Ct (2-ΔΔCt) 
method. Values are shown as mean ± SD. 
siRNA: Small interfering RNA; VEGFR1: Vascular 
endothelial growth factor receptor 1; SD: Standard deviation 
 
Western blot analysis: After analyzed on 
SDS-PAGE, protein were transferred to PVDF 
membrane using western blotting technique to 
analysis VEGFR1 protein level in AGS and 
SNU-5 cells. As shown in figure 2, cells treated 
with anti-VEGFR1 siRNA showed significant 
reduction of VEGFR1 protein level compared 
to untreated cells that expressed a 17kDa 
VEGFR1 band while. This shows that the use 
of anti-VEGFR1 siRNA targeted VEGFR1 
mRNA specifically, and influenced its protein 
production. β-actin was used and expressed as 
a positive control in this experiment. 
 
 
Figure 2. Analysis of siRNA effect on VEGFR1 
protein expression in AGS and SNU-5 cells 
using western blot. β-actin was used as positive 
control. Negative control is without protein. As 
shown, a 19 KDa protein was expressed in cells 
transfected without siRNA, but transfection with 
anti-VEGFR1 siRNA has significantly reduced 
the level of VEGFR1 protein. 
siRNA: small interfering RNA; VEGFR1: Vascular 
endothelial growth factor receptor 1 
 
Cell viability assay: MTT assay was 
performed to evaluate the viability of AGS and 
SNU-5 cancer cells transfected with anti-
VEGFR1 siRNA after 24, 48, and 72 hours. The 
results of MTT assay revealed that viability of 
AGS and SNU-5 cells treated with anti-
VEGFR1 siRNA significantly reduced in a 
time-dependent manner compared to 
untreated cells (Figure 3). This results 
indicated the cytotoxicity of VEGFR1 
suppression to these cancer cells. 
Apoptosis assay: To evaluate the number of 
apoptosis AGS and SNU-5 cells, Annexin-V-PI 
kit was used. With regards to MTT assay 
results, 72 hours post transfection with anti-
VEGFR1 siRNA, cells were collected and 
treated with Annexin V-FITC and PI, and 
analyzed by flow-cytometer, according to 
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Figure 3. Survival ratios of AGS and SNU-5 cells 
treated with anti-VEGFR1 siRNA. The 80% 
confluence cell cultures were treated with 
siRNA. Cell viability was significantly reduced 
in a time-dependent manner. At 48h after 
treatment more than 50% of cells die. Results 
represented as means of three independent 
experiments by MTT assay (P ≤ 0.050) 
siRNA: Small interfering RNA; VEGFR1: Vascular 
endothelial growth factor receptor 1; MTT: Methyl-
thiazol-tetrazolium 
 
Results of apoptosis assay revealed that the 
number of apoptotic cells had notably 
increased following transfection with anti-
VEGFR1 siRNA in comparison to non-
transfected cells. Total apoptosis had elevated 
3.7 and 3.2 times in treated group compared to 
control group in AGS and SNU-5 cells, 
respectively (Figure 4). 
Discussion 
VEGF and its receptors play a key role in the 
process of angiogenesis, which is an important 
factor in tumor growth and metastasis. Due to 
the increasing use of therapeutic inhibitors of 
VEGF signaling pathway in recent years, 
understanding the mechanisms underlying 
this pathway has become more important.32,33 
Previous studies had shown that of VEGFR-2 
activation can activate downstream signaling 
pathways including ERK, JNK, PI3K, AKT, 
P70S6K, and p38MAPK.32,34 
 
Figure 4. Flow Cytometry analysis of AGS and 
SNU-5 cells stained with Annexin V-FITC and PI. 
(A) Cells without treatment were used as controls. 
(B) Cells underwent apoptosis induced by anti-
VEGFR1 siRNA. Diagram Q1 to Q4 represents 
necrotic, early apoptotic, late apoptotic and live 
cells, respectively. Treated cells showed 
significantly increased in the rate of early and late 
apoptosis compared with control. 
siRNA: Small interfering RNA; VEGFR1: Vascular 
endothelial growth factor receptor 1 
 
In other hand, the function of VEGFR1 is 
not well established.35,36 Research on different 
kind of cancers including breast cancer, lung 
cancer, and gastric cancer has revealed that up-
regulation of VEGFR1 is associated with tumor 
growth, tumor cell activation, and 
metastasis,37-41 and its soluble form has been 
up-regulated in serum of patients with gastric 
cancer.42 Blocking the function of VEGF 
signaling pathway is an important therapeutic 
approach to control angiogenesis, tumor 
growth, and metastasis. Previous studies have 
reported co-expression of VEGF and VEGFR1 
in gastric cancer cell lines such as MGC803, 
AGS-1, RF-1, and RF-48, as well as specimens 
of gastric cancer.41 
Many different agents have been reported 
including chemical compounds and antibodies 
to block or suppress VEGF signaling pathways 
in goal of control angiogenesis, tumor growth, 
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suppress VEGF receptors to antagonize VEGF. 
In this strategy, several VEGF family members 
could be blocked at once. So, VEGF receptors 
have been considered as therapeutic targets for 
cancer therapy.43,44 Currently, about 44 VEGFR 
inhibitors such as novartis, axitinib, motesanib, 
sunitinib, and sorafenib are in clinical phase 
development, and some of them have been 
used for cancer therapy.45,46 Hwang et al. have 
reported that concomitant inhibition of 
VEGFR1 and VEGFR-2 with paclitaxel increase 
the TUBB3 expressing cancer cell line 
cytotoxicity, and their inhibition with 
paclitaxel, anti-VEGFR1, and anti-VEGFR-2 in 
AGS cell was more cytotoxic.42 Moreover, 
Zhang et al. reported that VEGFR1 was the 
dominant receptor in tumor 
microenvironment.6 Due to these findings, we 
have postulated that AGS and SNU-5 gastric 
cancer cell lines express VEGFR1.  
Here, we used anti-VEGFR1 siRNA to block 
VEGFR1 expression in AGS and SNU-5 cell 
lines. Our results revealed that mRNA and 
protein expression levels of VEGFR1 
significantly decreased in AGS and SNU-5 
cells 72 hours post transfection with siRNA 
compared to control group. These results 
demonstrated the efficiency of anti-VEGFR1 
siRNA to block VEGFR1 function. These 
findings are consistent with previous studies 
which demonstrated blockade of VEGFR1 
using anti-VEGFR1 antibodies or synthetic 
compounds, suppressed tumor growth and 
metastasis in vivo and in vitro.47,48 In addition, 
the results of MTT and apoptosis assays 
demonstrated down-regulation of VEGFR1 
could significantly inhibit cell growth and 
increase apoptosis of AGS and SNU-5 cells. 
Although, some studies have reported that 
blockade of VEGFR1 is not adequate without 
combined suppression of VEGFR-2 to inhibit 
tumor growth and cell proliferation,49,50 but 
other studies demonstrated that suppression of 
VEGFR1 signaling could inhibit the growth 
and survival of several mouse tumor models, 
and increase apoptosis of many cell lines.41,51,52 
A study by Szabo et al. on glioblastoma have 
revealed that shRNA down-regulation or 
blocking the phosphorylation of VEGFR1 in 
vitro and in nude mice could reduce tumor 
cells growth.53 Moreover, another research on 
tumor cell lines such as pancreatic and 
colorectal cancer cells have demonstrated a 
possible role for VEGFR1 in cell growth and 
survival.54 Furthermore, the inhibition of 
VEGFR1 signaling in CAKI1 and SKUT1b cells 
using siRNA oligonucleotides inhibited tumor 
growth, and decreased survival of cancer 
cells.41 These previous works support our 
findings, and indicate that blocking VEGFR1 
using RNAi mechanism suppresses cell 
proliferation and tumor growth, as well as 
induction of cancer cells apoptosis. 
Conclusion 
Our results showed that using specific siRNAs, 
to down-regulate the expression of VEGFR1 
and suppression of its function, can inhibit cell 
proliferation, and drive apoptosis of tumor 
cells. As previously proposed, and according 
to our findings, blocking of VEGFR1 can be 
considered as a therapeutic target to inhibit 
tumor growth. 
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